Saliva

Intelligent Bio Solutions Signs South American Distribution Agreement with TSCOM for Fingerprint Drug Screening System and Secures First Order

Retrieved on: 
Thursday, July 6, 2023
Partnership, Methamphetamine, Urine, Cocaine, Occupational safety and health, Cannabis, Intelligence, Saliva, Drug

The Company further announced it received its first order under this agreement, coming from a Chile-based electrical distribution company.

Key Points: 
  • The Company further announced it received its first order under this agreement, coming from a Chile-based electrical distribution company.
  • The Intelligent Fingerprinting solution, which is widely recognized as the world’s first fingerprint-based drug testing system, analyzes fingerprint sweat to screen for recent drug use, including cannabis, cocaine, opiates, and methamphetamine.
  • Pablo Riera, Director at TSCOM SPA, said, “At TSCOM, we’re looking forward to offering the innovative Intelligent Fingerprinting drug screening system to the South American market, and we’ll initially be targeting workplaces, government operations and healthcare providers across Chile.
  • We are currently carrying out training and helping the client as they introduce fingerprint testing in their workplace.”
    Harry Simeonidis, President and CEO of Intelligent Bio Solutions, commented, “Fingerprint drug testing is increasingly being regarded as the smart alternative for workplace drug screening.

IDENTIFYSENSORS BIOLOGICS ANNOUNCES NEW CLINICAL STUDIES GROUP TO VALIDATE DIGITAL DIAGNOSTIC DEVICES

Retrieved on: 
Wednesday, June 28, 2023
Norovirus, Rotavirus, HIV, Virology, SARS-CoV-2, Methicillin-resistant Staphylococcus aureus, Infection, Gonorrhea, Respiratory syncytial virus, Sale, Trial of the century, Hepatitis C, Chlamydia, B cell, FDA, Medeiros, PCR, Saliva, Medical device, Vaccine

CLEVELAND, June 28, 2023 /PRNewswire/ -- IdentifySensors® Biologics, a leading developer of digital diagnostic technologies, announces the formation of the company's new Clinical Studies Group, responsible for testing new diagnostic devices in preparation for FDA submissions.

Key Points: 
  • CLEVELAND, June 28, 2023 /PRNewswire/ -- IdentifySensors® Biologics, a leading developer of digital diagnostic technologies, announces the formation of the company's new Clinical Studies Group, responsible for testing new diagnostic devices in preparation for FDA submissions.
  • The group has started preparing for an extensive clinical study this fall of two multiplex respiratory devices intended to detect and differentiate SARS-CoV-2, Influenza A, Influenza B and respiratory syncytial virus in saliva.
  • The devices are intended to reduce costs and testing time, while increasing sensitivity and flexibility for clinicians and consumers.
  • "In preliminary studies we have seen encouraging results of this new technology," said Greg Hummer M.D., IdentifySensors® co-founder and CEO.

MeiraGTx Announces Positive Clinical Data from the AQUAx Phase 1 Clinical Study of AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia

Retrieved on: 
Tuesday, June 27, 2023
S&P Global Ratings, Gland, Xerostomia, Head, Bangladesh Technical Education Board, AQP1, Patient, Webcast, RIX, XQ, Safety, NIH, Saliva, Pharmaceutical industry, Birth control

ET

Key Points: 
  • ET
    LONDON and NEW YORK, June 27, 2023 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced positive clinical data from the completed Phase 1 AQUAx study of AAV2-hAQP1 for the treatment of grade 2/3 radiation-induced xerostomia (RIX).
  • “Today we are releasing data from the completed Phase 1 AQUAx study which now includes the final 12 month data from all bilaterally treated participants.
  • AQUAx is an open label, multi-center, dose escalation study of a single administration of AAV2-hAQP1 to one or both parotid glands in participants with radiation-induced salivary hypofunction and grade 2/3 xerostomia.
  • All participants were followed for 1-year post-treatment in the Phase 1 AQUAx study and were then enrolled in a long-term follow-up study for a total of 5 years.

Veravas Launches Groundbreaking VeraBIND Technology for Ultra-Sensitive Assays and Matrix Free Sample Analysis

Retrieved on: 
Tuesday, June 20, 2023
Urine, Quality of life, Research, Mass spectrometry, Biomarker, ELISA, Genetics, Collection, Patient, Blood, Diagnosis, Saliva, Medical imaging, Pharmaceutical industry, Alzheimer's disease

AUSTIN, Texas, June 20, 2023 /PRNewswire/ -- Today, Veravas, a leading innovator in clinical diagnostics, announced the launch of its groundbreaking VeraBIND™ (Biomarker Isolation and N-richment for Detection) technology. With millions of assays conducted daily in clinical laboratories worldwide, the search for specific biomarkers to identify early-stage diseases is becoming increasingly crucial. However, the inherent challenges posed by diverse patient sample types, including urine, saliva, and blood, can lead to false positive or negative results. VeraBINDing the sample during collection or preparation transforms complex samples into a matrix-free sample which enhances the performance of on-market tests and can allow healthcare professionals to realize a significant breakthrough in biomarker detection.

Key Points: 
  • However, the inherent challenges posed by diverse patient sample types, including urine, saliva, and blood, can lead to false positive or negative results.
  • VeraBIND technology offers a unique and comprehensive solution that improves the accuracy of biomarker detection and minimizes the occurrence of false positive or negative results across various sample types.
  • This advancement ensures assays leveraging VeraBIND can be standardized for more efficient analysis."
  • With VeraBIND, Veravas is redefining assay development and biomarker detection, setting a new standard in clinical diagnostics and research.

RICOVR Healthcare Announces Successful Validation of its P-FAB Technology for Detecting THC at Rutgers University

Retrieved on: 
Wednesday, June 14, 2023
Workforce, Biotechnology, Law enforcement, Mass spectrometry, Rutgers University, Biochemistry, Research and development, Molecular biology, Robert Wood Johnson Medical School, Saliva, JHSPH Department of Biochemistry and Molecular Biology, THC, Safety, Drug, Medical device, Pharmaceutical industry, Research, Princeton University

The P-FAB technology was 100% accurate compared to the gold standard mass spectrometry for detecting THC in human saliva. Rutgers University performed the testing services sponsored by RICOVR Healthcare.

Key Points: 
  • Princeton, New Jersey--(Newsfile Corp. - June 14, 2023) - RICOVR Healthcare , the creator of XALIVA® THC rapid drug test for on-site recent marijuana use detection, reports successful external validation of its P-FAB technology using mass spectrometry for detection of ∆9-tetrahydrocannabinol (THC) in saliva in collaboration with Rutgers University.
  • "The results from our validation with Rutgers University show that our P-FAB technology can provide a highly accurate, portable, fast, and cost-effective tool for recent marijuana use detection," said Dr. Joe Seimetz, RICOVR Healthcare's Director of Research and Development.
  • Thus, in this technology validation, the P-FAB device has 100% accuracy relative to the gold standard mass spec method.
  • Dr. David Sleat commented, "Our mass spec validation testing showed that Ricovr's novel P-FAB technology has the ability to generate semi-quantitative detection of THC.

CE Brands Expands Its Ecosystem With the Launch Of Vitalist: A New Connected Health Ecosystem at the Nexus of Health and Technology

Retrieved on: 
Tuesday, June 6, 2023
Blood, Ecosystem, Health, Data analysis, Biomarker, Saliva, Retail, Vitalism

CE Brands is expanding its ecosystem of watches and wearables with the launch of Vitalist, a connected health brand that aims to revolutionize the way we approach health and wellness.

Key Points: 
  • CE Brands is expanding its ecosystem of watches and wearables with the launch of Vitalist, a connected health brand that aims to revolutionize the way we approach health and wellness.
  • The Vitalist ecosystem is being launched as a complementary expansion to the company’s existing smartwatch branding and operations.
  • This expansion represents CE Brands' commitment to delivering cutting-edge solutions and empowering individuals to achieve optimal well-being.
  • Kalvie Legat, CEO at CE Brands, describes the brand as a vibrant and innovative force in the intersection of health and technology.

Global Exosome Market Research Report 2023-2030: Market Size, Forecasts, Trials, and Trends with Company Profiles of 118 Competitors - ResearchAndMarkets.com

Retrieved on: 
Friday, June 9, 2023
Health, Biotechnology, Karolinska Institute, Fresenius Medical Care, Partnership, Therapy, Urine, Takeda, Serum, Breast milk, Tears, Exosome, Liquid biopsy, Cancer, Lead, Immunity, MicroRNA, Research, Cell, Lung cancer, Biomarker, Inflammation, Regenerative medicine, Plasma, Seminal vesicles, Acquisition, MSC, Publication, DSM-IV codes, Patient, Medicine, CSF, Diagnosis, FDA, Fluid mechanics, Disease, Metastasis, Saliva, Prostate cancer, Medical device, Medical imaging, Pharmaceutical industry

The "The Global Exosome Market - Market Size, Forecast, Trials, and Trends, 2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "The Global Exosome Market - Market Size, Forecast, Trials, and Trends, 2023" report has been added to ResearchAndMarkets.com's offering.
  • To characterize the rapidly expanding exosome market, the analyst has released a 312-page global market report that explores the growing demand for exosome therapeutics, diagnostics, research tools, and manufacturing technologies.
  • The report reveals trend rate data for exosome patents, grants, scientific publications, and clinical trials.
  • It features company profiles for 118 global competitors from across the exosome marketplace.

Hememics Biotechnologies, Inc. and General Graphene Corporation Cement Strategic Partnership for Large-Scale Production of Graphene-Based Biosensors

Retrieved on: 
Thursday, June 8, 2023
Partnership, CSO, CVD, Ricin, SEB, Knowledge, Knoxville, Tennessee, Saliva, Vaccine, Medical imaging, Carbon fibers, Research

In the past nine months alone, Hememics in conjunction with General Graphene has manufactured more than 100,000 graphene biosensors.

Key Points: 
  • In the past nine months alone, Hememics in conjunction with General Graphene has manufactured more than 100,000 graphene biosensors.
  • As a pure-play graphene foundry, General Graphene seeks partners who possess the application expertise necessary to commercialize graphene-based applications.
  • Hememics has been an excellent fit for us with their vast knowledge and expertise in graphene-based biosensors," said Greg Erickson, CEO of General Graphene.
  • General Graphene Corporation is a pure-play CVD graphene foundry manufacturing large-area, roll-to-roll (R2R), chemical vapor deposition (CVD) graphene.

ImmVira presented latest encouraging clinical results of two proprietary products at ASCO 2023

Retrieved on: 
Wednesday, June 7, 2023
Abstract, Index, Biopsy, Hypertriglyceridemia, AE, Urine, DCR, Pembrolizumab, DLT, Trae tha Truth, Head, Common Criteria, CD8, ORR, ASCO, Sarcoma, Lymphocytopenia, Patient, Evaluation, Colorectal cancer, Melanoma, Blood, HNSCC, Mesothelioma, Periodic breathing, PD-1, Breast cancer, Tumor microenvironment, Society, SD, PR, Saliva, CTCAE, Pharmaceutical industry, Medical imaging, Fever

12 evaluable HNSCC patients who progressed after platinum-based chemotherapy and anti-PD-1/PD-L1 therapy achieved confirmed ORR of 25% and DCR of 50%, respectively.

Key Points: 
  • 12 evaluable HNSCC patients who progressed after platinum-based chemotherapy and anti-PD-1/PD-L1 therapy achieved confirmed ORR of 25% and DCR of 50%, respectively.
  • Trial results showed that, MVR-T3011 IT had excellent safety profile and clinical compliance.
  • Phase I clinical data was also selected to be published at ASCO this year.
  • We are expecting to report more intravenous clinical results in both U.S. and China in the future.

AAV Vector Shedding Assay-- Best Practices in Clinical Gene Therapy Method Development, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Monday, June 5, 2023
Trial of the century, Saliva, Plasma, Doctor of Philosophy, Drug development, Semen, Molecule, Urine, Blood, AAV, Molecular and Cellular Biology, Vaccine, MCB

TORONTO, Ontario, Canada, June 5, 2023 /PRNewswire-PRWeb/ -- Gene therapies have demonstrated to be life-changing therapies for many devastating diseases. The drug development path is not always straightforward and regulatory guidance is often vague about the details of some requirements. One of the requirements in clinical development is to monitor vector shedding to control the potential environmental risk associated with the therapy. The assay read-out is qualitative, providing the sponsor and investigator with the relevant information about vector-shedding clearance after therapy. A sensitive and reliable method is needed in several different matrices, usually including blood, plasma, faeces, semen, urine and saliva. This webinar will cover unique requirements and challenges in developing vector shedding assays like the AAV shedding assay, with applications.

Key Points: 
  • In this free webinar, learn about the unique requirements and challenges in developing vector shedding assays like the AAV shedding assay, with applications.
  • Attendees will get a review of best practices for developing a suitable qPCR-based vector shedding assay and how that data can be used and interpreted during the clinical study.
  • One of the requirements in clinical development is to monitor vector shedding to control the potential environmental risk associated with the therapy.
  • This webinar will cover unique requirements and challenges in developing vector shedding assays like the AAV shedding assay, with applications.